A side-by-side comparison of major society guidelines for diagnosing and treating perimenopause, including hormone therapy recommendations from NAMS, the Endocrine Society, AACE, and USPSTF.
Estrogen fluctuations during perimenopause increase the risk of new-onset depression, anxiety, and brain fog. Learn how clinicians diagnose and treat the mental health overlap.
Evidence-based nutrition, exercise, and lifestyle strategies for managing perimenopause symptoms, backed by major society guidelines and clinical trial data.
Evidence-based guide to caregiving after surgery, covering wound care, medication management, nutrition, mobility support, mental health, and when to call the surgeon.
A structured framework for tracking post-surgical recovery across wound healing, pain trajectory, clot risk, nutrition, and function, with guidance on which findings warrant escalation and which reflect normal variation.
Evidence-based guide for caregivers and families supporting someone with prediabetes, including lifestyle strategies, screening recommendations, shared-risk awareness, and practical tools from the ADA, CDC, and major clinical trials.
ADA criteria: fasting glucose 100-125 mg/dL, A1c 5.7-6.4%, or OGTT 140-199 mg/dL. Screening starts at age 35. See the full diagnostic algorithm.
A guide to exercise protocols for prediabetes, including specific intensity targets, resistance training recommendations, and the trial data behind each prescription.
Prediabetes management starts with lifestyle changes targeting 7% weight loss, then metformin for high-risk patients, then GLP-1 agonists if obesity persists.
A guide for caregivers and family members supporting someone with secondary hypogonadism, covering diagnosis, treatment options, emotional support strategies, and clinical resources.
A side-by-side comparison of major society guidelines for diagnosing and treating secondary hypogonadism, including diagnostic thresholds, treatment algorithms, and fertility-preserving options.
Secondary hypogonadism frequently co-occurs with depression, anxiety, and cognitive decline. Learn how hypothalamic-pituitary dysfunction links low testosterone to mental health conditions, and what evidence-based treatments can help.
Evidence-based guide on how tendinopathy intersects with depression, anxiety, and sleep disorders, plus integrated treatment strategies backed by clinical research.
A week-by-week tendinopathy monitoring schedule covering VISA scores, load progression, imaging triggers, and escalation criteria based on current clinical evidence.
Yes, genetics play a role: one affected parent raises your risk to 40%, but over 400 genes explain only 20% of it. Lifestyle cuts risk 58%.
A side-by-side comparison of ADA, AACE, Endocrine Society, and USPSTF guidelines for Type 2 Diabetes diagnosis, A1c targets, first-line therapy, and cardiovascular risk management.
Evidence-based nutrition plans, exercise protocols, and lifestyle changes for managing type 2 diabetes, including ADA and AACE guideline recommendations, macronutrient targets, and meal timing strategies.
No generic dapagliflozin yet in the U.S.; patent expires 2026. Farxiga runs ~$580/month vs. Jardiance ~$590 and Invokana ~$570. Compare costs and efficacy.
Evidence-based guide to handling a missed dose of Farxiga (dapagliflozin). Covers timing rules, pharmacokinetics, clinical context for type 2 diabetes, heart failure, and CKD indications, plus what requires a call to your prescriber.
Dapagliflozin is metabolized mainly by UGT1A9, not CYP enzymes; variants can shift drug exposure 15-55%, though no FDA dosing change is required.
A clinician-grade breakdown of dapagliflozin (Farxiga) pharmacokinetics covering absorption, distribution, metabolism, excretion, and real-world dosing implications backed by FDA label data and primary literature.
Dapagliflozin stays at 10 mg daily regardless of kidney function. Starts at eGFR ≥25; continue until dialysis or transplant. DAPA-CKD data included.
Early bladder cancer concerns with Farxiga were resolved after review; FDA signals now focus on DKA, serious UTIs and Fournier gangrene.
A guide to safely discontinuing Prolia (denosumab), including bisphosphonate bridging protocols, rebound fracture risks, bone turnover monitoring, and step-by-step transition timelines.
A late Prolia dose resets the next six-month date. Use an injection-record worksheet and compare the actual delay and fracture evidence.
Complete monitoring schedule for Prolia (denosumab), including baseline labs, calcium checks, DEXA timing, and adverse-effect screening, with PubMed-cited evidence.
A clinical review of the denosumab (Prolia/Xgeva) patent portfolio, biosimilar development pipeline, FDA regulatory pathway, and projected generic availability dates for patients and prescribers.
Low libido can signal testosterone deficiency, cardiovascular disease, diabetes, or depression. Learn what declining sex drive really means and evidence-based ways to restore it.
A longevity program combines biomarker testing, metabolic optimization, hormone therapy, and targeted pharmaceuticals to extend healthspan. This guide covers the evidence, components, costs, and who benefits most.
PCOS causes irregular periods, acne, hair loss, weight gain, and mood changes. Learn what polycystic ovary syndrome really feels like day to day and which treatments work.
Evidence-based Trulicity (dulaglutide) dosing guide for adults aged 30, 49 with type 2 diabetes. Covers starting dose, titration schedule, injection technique, missed-dose rules, and real-world clinical considerations.
A guide to dulaglutide (Trulicity) safety for adults aged 30 to 49, covering GI side effects, cardiovascular data from REWIND, pancreatitis risk, thyroid warnings, and practical monitoring advice.
Evidence-based guide to dulaglutide (Trulicity) food and supplement interactions, including effects on nutrient absorption, alcohol, fiber, and common vitamins.
Evidence-based guide to dulaglutide (Trulicity) dosing in patients with hepatic impairment, including pharmacokinetic data, clinical recommendations, and liver safety monitoring.
Evidence-based protocol for managing a missed Trulicity (dulaglutide) dose, including timing thresholds, double-dose risks, and how to get back on schedule safely.
A clinical review of dulaglutide (Trulicity) patent filings, exclusivity windows, biosimilar development, and projected generic availability for patients with type 2 diabetes.
A physician-level review of dulaglutide (Trulicity) real-world evidence from registries, claims databases, and post-marketing studies, including REWIND cardiovascular data and adherence outcomes.
Evidence-based guide to dulaglutide (Trulicity) dosing across all stages of renal impairment, including CKD stages 3-5 and dialysis, with FDA label data, REWIND renal outcomes, and AWARD trial pharmacokinetics.
A comprehensive review of dulaglutide (Trulicity) safety signals, FDA regulatory actions, boxed warnings, postmarketing surveillance findings, and clinical trial safety data from REWIND and AWARD trials.
A guide to Trulicity (dulaglutide) self-injection technique, covering pen anatomy, site selection, injection steps, needle-free design, and how to avoid common errors.
Evidence-based guide to using dulaglutide (Trulicity) in transplant recipients, people living with HIV, older adults, and other special populations. Includes dosing, safety data, and clinical considerations.
TRICARE covers Trulicity (dulaglutide) for type 2 diabetes with prior authorization. Learn the formulary tier, step therapy rules, PA criteria, appeal process, and out-of-pocket costs for military beneficiaries.
Evidence-based monitoring guide for dutasteride (Avodart) in adults aged 30-49, covering PSA adjustments, liver function, hormonal panels, and safety labs for BPH and hair loss.
Stopping dutasteride: what to record about urinary symptoms, PSA, hair changes and sexual effects, plus the six-month blood donation wait.
Evidence-based guide to dutasteride food and supplement interactions, including saw palmetto, St. John's wort, grapefruit, and fat-soluble vitamin concerns.
State Medicaid coverage for Avodart (dutasteride) varies widely. Learn formulary status, prior authorization requirements, step therapy rules, and how to appeal a denial.
Evidence-based guide to handling a missed dose of dutasteride (Avodart). Covers pharmacokinetics, the 5-week half-life advantage, clinical impact, and step-by-step instructions.
Evidence-based monitoring schedule for dutasteride (Avodart), including baseline labs, PSA adjustments, liver function testing, and follow-up exam intervals for BPH and hair loss.
Dutasteride's half-life is 5 weeks at steady state, the longest of any 5-alpha reductase inhibitor. FDA dose is 0.5 mg daily, no age adjustment needed.
A detailed look at dutasteride (Avodart) patent expiry dates, Paragraph IV challenges, generic approvals, and what the post-exclusivity market means for BPH and hair loss patients.
A clinical deep-dive into how CYP3A4, SRD5A1, SRD5A2, and androgen receptor gene polymorphisms influence dutasteride metabolism, efficacy, and side-effect risk.
A clinical deep-dive into dutasteride (Avodart) pharmacokinetics covering absorption, distribution, metabolism, elimination, its 5-week half-life, CYP3A4 metabolism, and DHT suppression kinetics.
A clinician-level review of dutasteride (Avodart) regulatory approvals across the US, EU, Canada, and UK, including BPH indications, off-label hair loss use, and key differences between jurisdictions.
A clinician-grade review of dutasteride (Avodart) safety signals, FDA label changes, the REDUCE trial prostate cancer finding, sexual adverse effects, and mental health concerns, with PubMed-cited evidence.
UnitedHealthcare typically covers Avodart (dutasteride) on Tier 3 with prior authorization for BPH. Learn formulary placement, PA criteria, step therapy rules, appeal steps, and cost-saving alternatives.
Evidence-based monitoring guide for empagliflozin (Jardiance) in geriatric patients 65+, covering renal function, volume status, ketoacidosis screening, and deprescribing considerations.
Standard empagliflozin dose is 10 mg daily, up to 25 mg for T2D. Heart failure and CKD stay fixed at 10 mg; renal function guides dosing, not age.
Took extra Jardiance? Know what to report to Poison Help, which symptoms need urgent care, and how to interpret the available overdose evidence.
Aetna (CVS Health) may cover enclomiphene citrate for secondary hypogonadism with prior authorization and step therapy. Learn PA criteria, appeal steps, formulary tier, and cost details.
Full drug-drug interaction profile for enclomiphene citrate, including CYP enzyme effects, hormonal co-therapies, and safety data from clinical studies.